United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

medihealth (northern) ltd - ursodeoxycholic acid - oral tablet - 300mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glenmark pharmaceuticals europe ltd - ursodeoxycholic acid - oral tablet - 300mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

galen ltd - ursodeoxycholic acid - oral capsule - 250mg

Ireland - English - HPRA (Health Products Regulatory Authority)

strides arcolab international limited - ursodeoxycholic acid - capsule, hard - 250 milligram(s) - bile acid preparations; ursodeoxycholic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

amdipharm limited - ursodeoxycholic acid - capsule, hard - 250 milligram(s) - bile acid preparations; ursodeoxycholic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

strides pharma (cyprus) limited - ursodeoxycholic acid - capsule, hard - 250 milligram(s) - bile acid preparations; ursodeoxycholic acid

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - ursodeoxycholic acid 300mg;  ;   - capsule - 300 mg - active: ursodeoxycholic acid 300mg     excipient: colloidal silicon dioxide gelatin magnesium stearate opacode black s-1-17822 opacode black s-1-17823 starch - chronic intrahepatic cholestatic diseases including primary biliary cirrhosis and primary sclerosing cholangitis. in primary biliary cirrhosis actigall improves liver enzymes and igm and prevents worsening of liver histology in patients with less advanced forms of the disease, ie, serum bilirubin less than 2 mg/dl and histologic changes in liver confined to the portal regions. prevention of complications of chronic liver disease has not been established.

Israel - English - Ministry of Health

cts chemical industries ltd, israel - ursodeoxycholic acid - tablets - ursodeoxycholic acid 100 mg - ursodeoxycholic acid - ursodeoxycholic acid - dissolution or reductin in size of radiolucent cholesterol in patient with a functioning gallbladder. treatment of chronic liver diseases including primary billiary cirrhosis, primary sclerosing cholangitis, cystic fibrosis associated liver disease, biliary atresia, chronic hepatitis, and alcohol cirrhosis.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - ursodeoxycholic acid - oral tablet - 150mg

Ireland - English - HPRA (Health Products Regulatory Authority)

auden mckenzie (pharma division) ltd - ursodeoxycholic acid - tablets - 150 milligram - bile acid preparations